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Abstract
Acute gastroenteritis (AGE) remains a common condition in both low- and high-income
countries. In Belgium, however, there is currently a lack of information on the societal health
and economic impact of AGE. We conducted a retrospective study using mortality and cause-
of-death data, hospital data, primary care data, health interview survey data and other pub-
lished data. We estimated the burden of illness during a 5-year period (2010–2014) in
Belgium in terms of deaths, patients admitted to hospitals, patients consulting their general
practitioner (GP) and cases occurring in the community. We further quantified the health
impact in terms of disability-adjusted life years (DALYs) and the economic impact in
terms of cost-of-illness estimates. We estimated 343 deaths, 27 707 hospitalised patients,
464 222 GP consultations and 10 058 741 episodes occurring in the community (0.91 cases/
person) on average per year. AGE was associated with 11 855 DALYs per year (107 DALY
per 100 000 persons). The economic burden was estimated to represent direct costs of €112
million, indirect costs of €927 million (90% of the total costs) and an average total cost of
€103 per case and €94 per person. AGE results in a substantial health and economic impact
in Belgium, justifying continued mitigation efforts.
Introduction
Acute gastroenteritis (AGE) is a common condition causing a significant disease burden
worldwide. The Global Burden of Disease study estimated that diarrhoea was a leading
cause of death with 1.7 million deaths in 2016 [1]. Although in high-income countries mor-
tality due to diarrhoeal diseases is low, AGE gives rise to numerous episodes, general practi-
tioner (GP) consultations and hospitalisations. The number of deaths, hospitalised patients,
GP consultations and cases occurring in the community can be described in a disease pyramid,
allowing for a more complete picture of the burden of illness [2, 3]. The disease pyramid
further provides a basis for quantifying the health and economic impact of AGE [4, 5].
Different data sources provide information on the AGE disease pyramid in Belgium, albeit
with varying degrees of completeness. All deaths and hospitalisations are registered and clas-
sified according to ICD coding. Systematic collection of data on AGE from GPs is however
more limited. Furthermore, AGE cases occurring in the community are difficult to estimate
as not all cases seek health care, especially when the disease is mild and self-limiting.
The aim of this study was to assess the health and economic impact of AGE in Belgium
using available data sources.
Materials and methods
Reference period and population
We performed a retrospective analysis of routinely collected health information from different
sources targeting the Belgian population for the years 2010–2014. This time period provided
the most complete coverage across databases. First, we reconstructed the AGE disease pyramid
by estimating the number of episodes, GP consultations, hospitalisations and deaths occurring
annually in Belgium. Then, we quantified the health impact in terms of disability-adjusted life
years (DALYs) and the economic impact in terms of direct and indirect costs.
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Reconstruction of the disease pyramid using different data
sources
Figure 1 summarises the different steps in the AGE disease pyra-
mid and the data sources mapped to each step. In what follows,
we describe the mapping for each step in more detail.
Mortality and cause-of-death data
Statbel, the Belgian national institute of statistics, is responsible
for the compilation of mortality and ICD-10 coded
cause-of-death data based on death certificates. In the current
study, only the underlying cause of death was taken into account.
The underlying cause of death is defined in accordance with the
encoding rules of the World Health Organization (WHO), as
the diseases or the injuries which initiate a chain reaction of mor-
bidities that finally led to death [6]. Cause-of-death data can be
extracted through the Standardized Procedures for Mortality
Analysis website (SPMA), available online through https://spma.
wiv-isp.be/. We extracted data for 2010–2014 from SPMA to
establish the number of deaths with the ICD-10 codes A00-09
(‘Diarrhoea and gastroenteritis of presumed infectious origin’)
as the underlying cause of death.
Hospital data
The Minimal Clinical Data (MCD) is a compulsory hospital data
registration system, providing summarised clinical and demo-
graphic information for all persons admitted to Belgian hospitals.
Participation to the MCD has been mandatory for all hospitals
since 1991, and is managed by the Federal Public Service
Health, Food Safety and Environment. Hospital data are available
for hospitalised episodes of AGE as a primary (main) or second-
ary (any non-primary) diagnosis, coded by ICD-9 until 2014. In
2015, the database shifted to ICD-10 coding, but data were not
available for the year 2015. We obtained the annual number of
hospitalised AGE cases during 2010–2014, by age, from MCD
as the number of persons admitted to hospital with AGE defined
by ICD-9 codes 001-009 as a primary or secondary diagnosis
during their hospital stay.
Primary care data
The two major sources of primary care data in Belgium are the
Belgian Sentinel Network of General Practices (SNGP) [7],
managed by Sciensano, the Belgian institute for health, and the
Intego network, managed by the Katholieke Universiteit Leuven
(KU Leuven) [8].
The Belgian SNGP comprises approximately 150 general
practices with one or more sentinel GPs who purposively record
routine clinical care data for the surveillance of different health
problems. The network covers between 1.4% and 1.8% of the
Belgian population throughout all regions. AGE was included in
the SNGP network surveillance in 2002. For each case, a question-
naire was completed containing patient characteristics and spe-
cific questions about the symptoms (number of loose stools/day,
fever, blood in stool, vomiting and dehydration), antibiotic pre-
scription and if a stool sample was requested. Information on
the age and gender distribution of the sentinel population is
lacking, therefore the same age and gender distribution as in
the complete Belgian population is assumed when calculating
the incidence rates. For the SNGP, a case of AGE was defined
as any episode with at least four loose stools/day or loose stool/
vomiting in combination of at least two other symptoms (fever
or blood in stool).
The Intego network, operational since 1994, is an electronic
patient record (EPR)-based network of 54 voluntarily participat-
ing GP practices in Flanders, the northern region of the country,
which all use the same EPR software. The network is coordinated
by the Academic Centre for General Practice at the KU Leuven
and covers approximately 2% of the Flemish population. The
Intego database primarily uses the International Classification
of Primary Care (ICPC) coding system to register GP diagnoses.
In this coding system, AGE may be classified as ICPC code
D70 (‘gastrointestinal infection’) or D73 (‘gastroenteritis
presumed infection’).
To estimate the number of GP consultations for AGE, we first
extracted from the Intego database the number of GP registrations
in Flanders with ICPC codes D70 or D73, by age, for the period
2010–2014. We then used the SNGP data for 2002 to extrapolate
the number of consultations to the other regions (i.e. the Walloon
and Brussels Capital Region), based on the proportion of
AGE-related consultations per region in 2002.
Health interview survey data
The Belgian Health Interview Survey (BHIS) has, to date, taken
place in 1997, 2001, 2004, 2008 and 2013 [9]. The main objective
of the BHIS is to describe in a representative manner the health
status, health behaviour and use of health services of the
Fig. 1. Data sources used to reconstruct the acute gastroenteritis disease pyramid in Belgium.
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Belgian population. The sampling design is a stratified clustered
multi-stage with municipalities as primary, households as second-
ary and individuals as the tertiary sampling units. Questions on
AGE have only been included in the BHIS 2001. In 2001, a
total of 12 111 people were interviewed. The AGE-specific ques-
tions asked if the participant had had an episode of AGE in the
last 2 weeks prior to interview. Cases of AGE in the BHIS 2001
were defined as every person who reported three or more loose
stools in a 24 h period during the 14 days prior to the interview,
without having reported having chronic bowel problems during
the past 6 months.
The number of community cases was estimated from the BHIS
2001 considering an average duration of symptoms of 1–5 days
[10]. In a baseline scenario, we estimated the number of commu-
nity cases by multiplying the number of positive respondents with
365/17, considering an average duration of symptoms of 4 days
(17 = 14 days + [4–1] days of symptoms). In alternative incidence
scenarios, we estimated the minimum number of cases considering
a 5-day duration of symptoms (number of positive responses ×
365/18), and the maximum number assuming the minimum
duration of 1 day for all cases (number of positive responses ×
365/14). In 2006, a rotavirus vaccine came on the market in
Belgium, and quickly achieved high uptake (mean uptake in
2012: 89%) [11]. We therefore further corrected the community
incidence for children 0–9 years old by applying the post-/pre-
vaccination proportionate decrease (76.9%) in AGE hospitalisa-
tions for this age group, as estimated previously [12] and assuming
that the decrease in community incidence would be the same as in
hospitalisations.
Disability-adjusted life years
The burden of AGE was evaluated in terms of DALYs, a summary
measure of population health that is widely used to quantify bur-
den of disease. DALYs were calculated as previously described
[13] by summing years of life lost (YLLs) and years lived with dis-
ability (YLDs). Estimations for YLLs were performed using the
standard life expectancy table from the Global Burden of
Disease study [1]. For the estimations of YLDs, we stratified
AGE cases into mild, moderate and severe and matched these
strata with the levels across the disease pyramid (i.e. cases occur-
ring in the community, GP visits and hospitalisations, respect-
ively). To ensure that each case would be categorised in one
part of the disease pyramid only we excluded the number of
severe cases from the moderate cases and the number of moderate
and severe cases from the number of mild cases. In a baseline
scenario, we used the disability weights from Salomon et al.
[14] – i.e. 0.074, 0.188 and 0.247, for mild, moderate and severe
AGE, respectively. The duration of symptoms was set as 3 days
for mild AGE (community cases), 10 days for moderate AGE
(when a GP was consulted) and 14 days for severe AGE (hospital-
isation cases) [15]. In an alternative disability weight scenario, we
used the annual profile disability weights from Haagsma et al.
[15] – i.e. 0.000, 0.015 and 0.041 for mild, moderate and severe
AGE. DALYs are presented as the total number in Belgium per
year, as number of DALYs per 100 000 persons and as number
of DALYs per 100 000 cases.
Cost-of-illness
The economic impact of AGE was calculated considering direct
medical costs, direct non-medical costs and indirect costs. We
estimated the total cost-of-illness from a societal perspective
using data on the total number of AGE cases per age group, the
volumes (number of consultations, hospitalisations, medication
packages) for use of resources and the unit costs of each of
these items. As such, the average costs per case in a certain age
group was calculated and subsequently multiplied by the total
number of cases in each age group [5, 16, 17]. Then, the total
absolute cost-of-illness of AGE in Belgium and per case was
calculated by summing costs across all age groups. Our
cost-of-illness estimates were in line with the Belgian guidelines
for economic evaluations and budget impact analyses, developed
by the Belgian Healthcare Knowledge Centre (KCE) [18].
Direct costs
We estimated the total direct medical costs as the sum of the costs
for consultations at GPs and/or specialists, hospital admissions,
prescribed and over-the-counter medication, and laboratory
stool tests for diagnostic purposes. Unit costs for GP or specialist
consultations as well as for hospitalisations were obtained from
the National Institute of Health and Disability Insurance
(NIHDI) for 2016 (www.inami.fgov.be). The direct cost per GP
consultation was €24.48. For consultation of gastroenterologist,
a cost of €36.74 was used, and in the absence of reliable data,
we assumed that a 14% fraction of the people that visited a GP
consulted a specialist [19]. We used a mean duration of 4.4
days per hospitalisation and a mean cost of €2800 per hospitalisa-
tion day as estimated by NIHDI (https://tct.fgov.be/webetct/etct-
web/). For the prescribed and the over-the-counter medications,
we considered three main categories: antidiarrhoeal drugs (AD,
domperidone; €7.2 per package); oral rehydration solutions
(ORS; €9 per package); and antibiotics (AB, amoxicillin and cla-
vulanic acid; €10.41 per package) (prices derived from the Belgian
Center for Pharmacotherapeutic Information). The proportions
of episodes in which these drugs were used, i.e. 4.3% for AD,
7.4% for ORS and 6.5% for AB, were taken from a previous
study [5]. For the diagnostic stool tests, we assumed that 13.5%
of the GP visits resulted in the prescription of diagnostic stool
tests with a unit cost of €60 per test [5].
For the direct non-medical costs, we considered travel costs to
and from the GP and the hospital as previously estimated in the
Netherlands [5]. The average distance from a Belgian household
to their GP was set to be 1.8 km as in the Dutch study, consider-
ing the same population density. We further assumed that half of
the patients used a car (or other paid transport), while the other
half used a bicycle or went on foot [5]. The average distance from
a Belgian household to the nearest general hospital was set to be
7.0 km as in the Dutch study; we further assumed that all patients
used paid transport to go to the hospital [5]. For all paid trans-
ports, we used a cost of €0.30/ km [18] and no parking costs
were included. We did not consider costs for additional cleaning
material and diapers for patients in the absence of reliable data for
the estimations. For the pharmacy, we did not estimate any add-
itional costs as we considered that usually people went on foot or
bought the medication on the way to the GP.
Indirect costs
We associated indirect costs with losses due to absence from work
using two scenarios. According to the baseline scenario, we
assumed that in 37% of adult episodes (18–64), and in 18.6% of
the episodes in children (0–17) and seniors (65+), an employed
Epidemiology and Infection 3
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adult had to be absent from work due to AGE, as previously
described in a recent survey in the Netherlands [20]. The average
number of working days that an employee was absent from work
due to gastroenteritis (3.5 days) was retrieved from Securex, one of
the largest human resource companies in Belgium. The number of
absenteeism episodes was multiplied with the average number
of absence days from work per episode and then multiplied
with the average daily gross salary of €257 (2010 average) [18]
per working day to estimate the total costs.
According to an alternative scenario for estimating indirect
costs, we assumed that only people who asked for medical advice,
i.e. the moderate or severe cases, were absent from work. Indeed,
in Belgium, a medical certificate is needed to justify absence from
work. We estimated the workdays lost by multiplying the sum of
people that visited a GP, a specialist or had been hospitalised with
the average number of working days that an employee was absent
from work due to gastroenteritis (3.5 days) as described above. We
considered age group-specific employment rates using Eurostat
data for 2012 – i.e. 25.3% for ages 18–24, 79.3% for ages 25–54
and 39.5% for ages 55–64. We assumed that for children (0–17)
and elderly people (65+), at least one productive adult was taking
care of them and was absent from work for 1 day in case of a
moderate episode and for 2 days in case of a severe episode [17].
Results
Disease pyramid
The disease pyramid of AGE in Belgium is presented in Table 1.
We estimated an average of 10 058 741 community cases per year
in Belgium during the study period, corresponding to 0.91 cases/
person per year (range 0.86–1.1 cases/person per year) in an
average population of 11 052 385. The alternative incidence scen-
arios yielded a minimum and a maximum estimate of 9.5 and
12.2 million community cases, respectively. Cause-of-death data
yielded an average of 343 (217–408) AGE deaths per year, corre-
sponding to 3.1 deaths/100 000 persons, or 2.9 deaths/100 000
community cases (Supplementary Table S1). Hospital data
yielded an average of 27 707 (26 312–29 217) AGE hospitalisa-
tions per year, corresponding to 251 hospitalisations/100 000 per-
sons or 275 hospitalisations/100 000 community cases. Based on
primary care data, we estimated 464 222 GP consultations due
to AGE on average per year (460 187–466 602), corresponding
to 4200 consultations/100 000 persons, or 4450 consultations/
100 000 community cases.
Disability-adjusted life years
During 2010–2014, the fatal AGE cases resulted in an annual
average of 3509 YLLs. This corresponds to an annual rate of 32
YLLs per 100 000 persons and 35 YLLs per 100 000 cases
(Table 2). In our baseline disability weights scenario, 8346 years
of life were lost on average per year due to disability in
Belgium, corresponding to 83 YLDs per 100 000 cases/year and
76 YLDs per 100 000 persons/year. Mild AGE cases contributed
the most to the YLD estimate (70%), followed by moderate
(27%) and severe cases (3%) (Table 2). In total, AGE was respon-
sible for 11 855 DALYs per year in Belgium during 2010–2014,
corresponding to 107 DALYs per 100 000 persons and 118
DALYs per 100 000 cases.
Using the alternative disability weights scenario, we estimated
6548 YLDs for the moderate cases and 1136 YLDs for the severe
cases of AGE, while this approach resulted in zero YLDs for mild
cases. Consequently, the total estimated DALYs were 11 192,
Table 1. Estimated disease pyramid of acute gastroenteritis cases in Belgium, 2010–2014
Component
Number of cases
2010 2011 2012 2013 2014 Average
Deaths 408 362 217 387 339 343
Hospitalisations 27 699 26 652 28 654 29 217 26 312 27 707
GP consultations 460 187 463 267 465 081 465 975 466 602 464 222
Community cases, baseline estimate 9 920 001 10 010 579 10 075 302 10 121 939 10 165 885 10 058 741
Community cases, minimum estimate 9 368 890 9 454 436 9 515 563 9 559 610 9 601 114 9 499 922
Community cases, maximum estimate 12 045 716 12 155 704 12 234 296 12 290 926 12 344 289 12 214 186
GP, general practitioner.
Table 2. Estimated annual disease burden of acute gastroenteritis (AGE) in Belgium, 2010–2014 (baseline scenario)
Health state Cases YLDs YLLs DALYs DALYs/1000 casesa DALYs/100 000 total cases DALYs/100 000 persons
AGE, mild 9 594 519 5836 N/A 5836 0.61 58 53
AGE, moderate 436 515 2248 N/A 2248 5.15 22 20
AGE, severe 27 707 262 N/A 262 9.47 2.61 2.37
AGE, deaths 343 N/A 3509 3509 10 229 35 32
TOTAL N/A 8346 3509 11 855 N/A 118 107
aDALYs per 1000 mild, moderate or severe cases, respectively.
YLDs, years lived with disability; YLLs, years of life lost; DALYs, disability-adjusted life years; N/A, not applicable.
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corresponding to 101 DALYs per 100 000 persons and 111
DALYs per 100 000 cases (Supplementary Table S2).
Cost-of-illness
We estimated the direct medical costs at €112 million, or €11 per
case and €10 per person, accounting for 11% of the total costs
(Table 3). Nearly 70% of direct medical costs were due to hospi-
talisation (€78 million), while another 15% was due to the medi-
cation (€17 million). The direct non-medical costs (i.e. the
patients’ transport costs) were lower, contributing only €402
144. We estimated the indirect costs as €927 million accounting
for 90% of the total costs according to baseline scenario, or €85
per case and €84 per person. In the alternative indirect cost scen-
ario, we estimated an indirect cost of €98 million or 47% of total
costs, corresponding to €10 per case and €9 per person (Table 3).
In Belgium, the annual total costs for AGE under the baseline
scenario amounted to €1 billion on average during the study per-
iod. This is equivalent to an average of €103 per case and €94 per
person (Table 3). Using the alternative indirect cost scenario, we
estimated the total costs at €210 million, or €21 per case and €19
per person (Table 4).
Discussion
We performed to our knowledge the first assessment of the health
and economic burden of all-cause AGE in Belgium. During 2010–
2014, we estimated 0.91 AGE cases per person per year, resulting
in 12 000 DALYs and a total cost of €1 billion, corresponding to
€103 per AGE case when productivity losses were included. The
estimated costs when productivity losses related to time off
from work were excluded were considerably less, namely €112
million at an average cost per case of €11.
As in other high-income countries, AGE is common and
represents a significant burden to society in Belgium. Our AGE
incidence (0.91 cases/person per year) is at the lower end of the
range of AGE incidences estimated from retrospective surveys
in other high-income countries [21–24]. A review of estimates
Table 3. Estimated annual direct and indirect costs of acute gastroenteritis in Belgium, 2010–2014
Unit costa Average estimated units used per year Total costs
TOTAL COSTS 1 039 451 369
Direct costs 112 167 401
Direct medical costs 111 765 256
Consultation with a general practitioner 24.48 464 222 11 364 155
Consultation with a specialist 36.74 64 991 2 387 772
Hospitalisation 2800 27 707 77 579 600
Antibiotics 10.41 653 974 6 807 868
Oral rehydration solutions 9 747 399 6 726 588
Antidiarrhoeals 7.2 435 983 3 139 075
Stool tests 60 62 670 3 760 198
Direct non-medical costs 402 144
Transport from and to the doctor 1.08 264 607 285 775
Transport from and to the hospital 4.2 27 707 116 369
Indirect costs 927 283 968
Productivity losses – children 257 272 795 70 108 224
Productivity losses – adults 257 3 335 314 857 175 744
aPrices in euros.
Table 4. Estimated annual indirect and total costs of acute gastroenteritis in Belgium, 2010–2014 (alternative scenario)
Unit costa Average estimated units used per year Total costs
TOTAL COSTS 210 060 243
Indirect costs 97 892 842
Productivity losses 0–17 257 100 528 25 835 696
Productivity losses 18–24 257 16 714 4 295 498
Productivity losses 25–54 257 197 472 50 750 304
Productivity losses 55–64 257 13 510 3 472 070
Productivity losses 65+ 257 52 682 13 539 274
aPrices in euros.
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of the incidence and prevalence of AGE from 33 studies from
high-income countries has shown a range from 0.1 to 3.5 episodes
per person year [25]. However, our estimates for the episodes
occurring in the community are based on the BHIS conducted
nearly 20 years ago and it is unknown if the incidence has chan-
ged through these years. Although our estimates were similar to
most other countries, more recent data are necessary to confirm
the current burden of AGE at community level.
Interestingly, the implied proportion of cases consulting a GP
(5%) was at the lower end of the range of reported estimates from
other countries, i.e. 4–33% [5, 21, 26, 27]. Nevertheless, the GP
consulting rate was expected to be high in Belgium as a GP cer-
tificate is generally needed to justify absence from work. These
discrepancies might imply an overestimation of the number of
community cases in our study, or an underestimation of the num-
ber of GP consultations, or both. The discrepancies could also be
the result of differences in study design or case definitions across
studies, or of different healthcare systems and healthcare-seeking
behaviour across countries.
DALY calculations complement information on disease inci-
dence and mortality. Our estimate of 118 DALYs per 100 000
cases, which represents the patient burden, is very low in com-
parison with most of the infectious diseases occurring in several
countries in EU and globally [28–30]. However, the total burden
of the disease per 100 000 persons, driven by the large number of
episodes, is higher than each of the 31 communicable diseases in a
recent European study, including influenza, tuberculosis and
HIV/AIDS [28]. Our results further indicated that the DALYs
associated with mortality were only a small fraction of the total
DALYs (30%), while the morbidity impact accounted for 70%.
This is a reflection of the low case fatality ratio of AGE in high-
income countries, particularly compared with low-income coun-
tries, where mortality remains the dominant contributor to the
AGE disease burden [30].
Studies on the economic burden of AGE conducted in other
countries mainly focused on only health care costs [31, 32], gastro-
intestinal disease (acute and chronic) [33–35], foodborne gastro-
enteritis [36–38] or specific pathogens [31, 39, 40]. Therefore,
their results are difficult to compare with ours. The estimated eco-
nomic burden (including direct and indirect costs) of gastrointestinal
infections or foodborne illnesses in high-income countries varies
between €14 in Australia and €1305 in the USA per case [31].
The estimates of a study conducted in the Netherlands in 2004
yielded estimates comparable with ours – i.e. a total cost of €77
per case and indirect costs representing 82% of the total costs [5].
Our study has several limitations. First and foremost, our dis-
ease pyramid estimates are limited by the inherent limitations of
each of the applied data sources. For the community cases, the
only available database was the BHIS performed in 2001. Since
this database has a very short recall period (14 days) and probably
overestimates the real incidence of the disease [26], we corrected
the estimates by inserting the disease duration in the calculations.
Our scenario analyses based on a minimum and a maximum dur-
ation of symptoms of 0 and 5 days showed that our estimate was
relatively robust against this assumption. For the GP consulta-
tions, the only available nationally representative data (SNGP)
were for the year 2002, while the most recent data (Intego) were
only available for Flanders. Furthermore, it is possible that one
AGE event resulted in more than one GP consultation; however,
Intego data show that for the vast majority of events, only one
consultation was registered. Finally, our death estimates were
derived from cause-of-death data considering only the underlying
cause. Nonetheless, AGE could have contributed to the death
without being listed as the underlying cause. Over the 5-year
study period, in addition to the 1713 AGE deaths, another 297
(59 per year) had ICD-10 codes A00-09 listed in the chain of
events leading to death, but without being the underlying cause
of death. Including these deaths would have resulted in a 17%
increase in the number of AGE deaths, and a consequent increase
in the number of YLLs and DALYs. However, it is common prac-
tice in burden of disease studies to assign deaths only to the
underlying cause of death, thus avoiding double-counting when
deaths would be assigned to more than one cause.
In addition to the inherent biases in the individual data
sources, across data sources, case definitions were not constant.
The exact impact of this limitation is difficult to ascertain.
Furthermore, we used a 5-year reference period, 2010–2014, to
average out possible aberrant temporal variations. The study per-
iod was further driven by the availability of data across data
sources. In particular, the last available MCD data according to
ICD-9 classification were from 2014; in 2015, MCD data were
not available due to transforming to ICD-10 coding.
For the DALY calculations, we used two different approaches for
defining morbidity-associated health losses, in line with current
major studies [14, 40]. Interestingly these two estimations were
only 9% different, suggesting that the overall estimates are robust.
However, the YLD estimates by severity level did differ significantly.
Our cost-of-illness estimates were generally limited by a lack of
recent and nationally representative data on healthcare use and
productivity losses, and should therefore be interpreted with cau-
tion. The current estimates are therefore partially based on data
from other countries [5], data from studies regarding different
diseases [17, 19] or expert advices. Data were particularly lacking
for estimating indirect costs. We considered two scenarios for esti-
mating the extent of absenteeism among patients and caregivers,
which resulted in widely different estimates, ranging from €927
million in our baseline scenario to €98 million in a more conser-
vative alternative scenario. The important contribution of prod-
uctivity losses clearly warrants further nationally representative
surveys to address this gap. A key data gap was the absenteeism
associated with AGE in older adults (65+), who account for an
important proportion of the AGE cases. As most surveys focus
on AGE in children and their parents, little is known about the
consequences for older adults and their caregivers. In both scen-
arios, we therefore assumed the same levels of absenteeism for
caregivers of children and elderly adults, which may have been
an overestimation of the indirect cost. Furthermore, we excluded
certain cost components due to general lack of data, such as non-
specified over-the-counter medication, taxi use, parking expenses
or additional cleaning material and diapers. We also did not con-
sider the possible use of leftovers from previously bought medica-
tion from the patients with AGE, which led to an overestimation
in our cost estimates; however, the effect of these aspects on the
total cost estimates are not likely to be substantial.
Despite these limitations, our results indicate major health and
economic losses associated with AGE morbidity in Belgium. To sup-
port risk management, further studies are needed to unravel the rela-
tive contribution of specific pathogens to the AGE burden, as well as
the role of community-acquired vs. hospital-acquired AGE.
Conclusions
AGE results in a substantial health and economic impact in
Belgium, justifying continued mitigation efforts. Nationally
6 Theofilos Papadopoulos et al.
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representative surveys are needed for addressing several of the
identified data gaps, while further research is needed to identify
the aetiologies underlying AGE in Belgium to support appropriate
interventions.
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